DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20212342

Common complications post-kidney transplantation: a literature review

Talal M. Al-Amri, Yousef H. Alharthi, Abdullah S. Alkhamis, Ali I. A. Muhaif, Mohammad A. Almutairi, Narjes M. A. Mousa, Ali A. Awkar, Nawaf A. Yahya, Wajdi I. Abbas, Omar A. Nass, Dhiyaa A. Alibrahim

Abstract


The most efficacious management modality for patients with end-stage renal disease is kidney transplantation. Although dialysis of the conditions and obstacles might be a temporary solution, it has been previously correlated with increased risk of many complications, including mortality and reduced health-related quality of life. In this literature review, the aim to discuss the commonly reported complications of post-kidney transplant, including complications that are usually caused by immune-mediated pathologies and non-immunological. Nevertheless, allograft rejection post-kidney transplant is the most common reported immunological complication following transplantation because it can be acute, subacute, accelerated, or chronic. However, after induction of the immunosuppressive modalities, the rates of graft rejections were significantly reduced but many other drug-related complications and have emerged as post-transplantation DM, malignancies, cardiovascular diseases, and infections. Many risk factors for developing post-transplant DM have been reported in the literature, such as the type of the administered immunosuppressive modality, obesity, ethnicity, hypomagnesemia, cytomegalovirus (CMV), and hepatitis C viral (HCV) infections. Early identification and adjustment of the risk factors for these modalities might be associated with significant improvement in prognostic outcomes. The most commonly diagnosed post-transplant carcinomas, including renal cell carcinoma, squamous cell cancer of the lip and skin, salivary gland cancer, and cholangiocarcinoma. Besides, HCV, CMV, and BK virus were the most commonly reported infections following kidney transplantation.


Keywords


Kidney transplantation, Complications, Mortality, Morbidity, Immunity

Full Text:

PDF

References


Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Adv Ther. 2016;33(3):345-56.

Sellarés J, de Freitas DG, Mengel M. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-99.

Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81(5):643-54.

Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4(3):378-83.

Haberal M, Boyvat F, Akdur A, Kırnap M, Özçelik Ü, Yarbuğ Karakayalı F. Surgical Complications After Kidney Transplantation. Exp Clin Transplant. 2016;14(6):587-95.

Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178-85.

Becker LE, Morath C, Suesal C. Immune mechanisms of acute and chronic rejection. Clin Biochem. 2016;49(4-5):320-3.

Hara S. Current pathological perspectives on chronic rejection in renal allografts. Clin Exp Nephrol. 2017;21(6):943-51.

El Ters M, Grande JP, Keddis MT. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant. 2013;13(9):2334-41.

Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004;78(2):242-9.

Stegall MD, Park WD, Larson TS. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant. 2011;11(4):698-707.

Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant. 2010;10(5):1126-34.

Haas M, Loupy A, Lefaucheur C. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307.

Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983;6(1):23-5.

Sharif A, Cohney S. Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol. 2016;4(4):337-49.

Hart A, Smith JM, Skeans MA. OPTN/SRTR 2016 Annual Data Report: Kidney. Am J Transplant. 2018;18(1):18-23.

Kamar N, Toupance O, Buchler M. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14(8):2092-8.

Gürsoy M, Güvener N, Köksal R. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc. 2000;32(3):561-2.

Sood A, Hakim DN, Hakim NS. Consequences of Recipient Obesity on Postoperative Outcomes in a Renal Transplant: A Systematic Review and Meta-Analysis. Exp Clin Transplant. 2016;14(2):121-8.

Sharif A, Hecking M, de Vries AP. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992-2000.

Ekberg H, Tedesco-Silva H, Demirbas A. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-75.

Wissing KM, Abramowicz D, Weekers L. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am J Transplant. 2018;18(7):1726-34.

Engels EA, Pfeiffer RM, Fraumeni JF. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-901.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.

Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis. Am J Transplant. 2016;16(12):3490-503.

Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. Am J Transplant. 2016;16(2):565-73.

Hall EC, Engels EA, Pfeiffer RM, Segev DL. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015;99(5):1051-7.

Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905-13.

Martin ST, Powell JT, Patel M, Tsapepas D. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Health-System Pharm. 2013;70(22):1977-83.

Vincenti F, Blancho G, Durrbach A. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9):1587-96.

Opelz G, Unterrainer C, Süsal C, Döhler B. Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. Nephrol Dialysis Transplantation. 2016;31(10):1730-8.

Guba M, von Breitenbuch P, Steinbauer M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med. 2002;8(2):128-35.

Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003;63(3):917-26.

Knoll GA, Kokolo MB, Mallick R. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:6679.

Yanik EL, Gustafson SK, Kasiske BL. Sirolimus use and cancer incidence among US kidney transplant recipients. Am J Transplant. 2015;15(1):129-36.

Ying T, Wong G, Lim W. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. Am J Transplant. 2018;18(12):2977-86.

Nee R, Hurst FP, Dharnidharka VR, Jindal RM, Agodoa LY, Abbott KC. Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation. 2011;92(2):190-5.

KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(3):1-155.

Nakano T, Ninomiya T, Sumiyoshi S. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Transplant. 2010;55(1):21-30.

Ramphul R, Fernandez M, Firoozi S, Kaski JC, Sharma R, Banerjee D. Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol. BMC Nephrol. 2018;19(1):2.

Lentine KL, Costa SP, Weir MR. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434-80.

Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17(3):900-7.

Rao NN, Coates PT. Cardiovascular Disease After Kidney Transplant. Sem Nephrol. 2018;38(3):291-7.

Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation. F1000 Res. 2019;8:F1000.

Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation. F1000 Res; 2019: 8.

Fishman JA. Infection in Organ Transplantation. Am J Transplant. 2017;17(4):856-79.

Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant. 2014;14(10):2206-20.

Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5(1):139-44.

Kotton CN, Kumar D, Caliendo AM. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333-60.

Hirsch HH, Knowles W, Dickenmann M. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-96.